Shinichi Ohkawa
Yokohama, 2418515, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Therapeutic Outcome of Multidisciplinary Treatment in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Analysis.
Journal: World journal of oncology
Published: January 17, 2024
Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study.
Journal: Oncology letters
Published: April 28, 2022
Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer.
Journal: Nutrition and cancer
Published: January 13, 2021
Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
Journal: Digestion
Published: January 29, 2020
Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer.
Journal: Nature communications
Published: September 10, 2019
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.
Journal: Internal medicine (Tokyo, Japan)
Published: June 28, 2019
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Journal: Neuroendocrinology
Published: June 27, 2019
Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pancreatic cancer.
Journal: American journal of cancer research
Published: September 04, 2018
Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD).
Journal: Japanese journal of clinical oncology
Published: August 20, 2018
SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated With Gemcitabine, S-1, or Gemcitabine Plus S-1.
Journal: Pancreas
Published: April 24, 2018
Prediction model for pancreatic cancer risk in the general Japanese population.
Journal: PloS one
Published: April 10, 2018
Last Updated: 09/26/2026